News for Almirall, S.A. (LBTSF)

Almirall, S.A. (OTCPK:LBTSF) Q3 2024 Earnings Conference Call November 11, 2024 4:00 AM ETCompany ParticipantsPablo Divasson - Investor RelationsCarlos...

Almirall, S.A. press release (LBTSF): nine-month 2024 net sales increased by 7.9% YoY to a total of €727.6 MM, EBITDA was €142.2M (increase of 2.9% Y/Y) driven by higher sales growth,

Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe

Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress

Almirall, S.A. (OTCPK:LBTSF) Q2 2024 Earnings Conference Call July 22, 2024 4:00 AM ETCompany ParticipantsPablo Divasson - Investor RelationsCarlos Gallardo...

The following slide deck was published by Almirall, S.A.

Almirall's H1 2024 Results: Almirall Delivers Strong Performance in the First Half of 2024, Achieving Net Sales Growth of 6.7% Driven by Its European Dermatology Business and Accelerating Biologics

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe Atopic Dermatitis in the NHS England in Eligible Adolescents and Adults

Almirall, S.A. (OTCPK:LBTSF) Q1 2024 Results Conference Call May 13, 2024 4:00 AM ETCompany ParticipantsPablo Divasson - Director, IR and Corporate...

The Global Topical Antibiotics Market Size was Valued at USD 5.25 Billion in 2023 and the Worldwide Topical Antibiotics Market Size is Expected to Reach...

Evolving regulations regarding antibiotic use and manufacturing standards impact market dynamics and product offerings....

Increase in launch of novel acne products and rising demand for personal wellness and smooth spotless skin due to high psychological burden associated with...

Almirall, S.A. (OTCPK:LBTSF) Q2 2023 Earnings Conference Call July 24, 2023 4:00 AM ETCompany ParticipantsPablo Divasson - Director of Investor Relations and Corporate CommunicationsCarlos...